Abstract:Despite the progress made with the recent clinical use of the anticancer compound cabazitaxel, the efficacy in patients remains unsatisfactory, largely due to the high in vivo toxicity of the agent. Therefore, strategies that achieve favorable outcomes and good safety profiles will greatly expand the repertoire of this potent agent. Here, we propose a combinatorial strategy to reform the cabazitaxel agent and the use of sequential supramolecular nanoassembly with liposomal compositions to assemble a prodrug-formulated liposome, termed lipoprodrug, for safe and effective drug delivery. Reconstructing cabazitaxel with a polyunsaturated fatty acid (i.e., docosahexaenoic acid) via a hydrolyzable ester bond confers the generated prodrug with the ability to be readily integrated into the lipid bilayer of liposomes for systemic administration. The resulting lipoprodrug scaffold showed significantly sustained drug release profiles and improved pharmacokinetics in rats as well as a reduction in systemic toxicity in vivo. Notably, the lipoprodrug outperformed free cabazitaxel in terms of in vivo therapeutic efficacy in multiple separate tumor xenograft-bearing mouse models, one of which was a patient-derived xenograft model. Surprisingly, the lipoprodrug was able to reduce tumor invasiveness and reprogram the tumor immunosuppressive microenvironment by proinflammatory macrophage polarization. Our findings validate this lipoprodrug approach as a simple yet effective strategy for transforming the highly toxic cabazitaxel agent into an efficacious nanomedicine with excellent in vivo tolerability. This approach could also be applied to rescue other drugs or drug candidates that have failed in clinical trials due to poor pharmacokinetic properties or unacceptable toxicity in patients.

Probing the new strategy for the oral formulations of taxanes: changing the method with the situation

Advances in strategies of improving solubility and permeability of taxanes

Novel formulations of taxanes: a review. Old wine in a new bottle?

Advances in the formulations of non-injection administration of docetaxel.

Taxanes prodrug-based nanomedicines for cancer therapy

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Novel Oral Administrated Paclitaxel Micelles with Enhanced Bioavailability and Antitumor Efficacy for Resistant Breast Cancer.

Emerging nanotaxanes for cancer therapy

Current development in the formulations of non-injection administration of paclitaxel

Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.

Enabling oral novel Taxanes-based Chemotherapy with Lipophilic prodrug Self-nanoemulsifying drug delivery system

Taxane anticancer agents: a patent perspective

Current development in nanoformulations of docetaxel.

Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy

Current Development in Nanoformulations of Docetaxel

A multiscale approach to targeted docetaxel formulations: combination therapy, nanotechnology, electrospinning and 3D printing—a review

Pharmaceutical nanotechnology for oral delivery of anticancer drugs.

Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration

Innovative strategies for effective paclitaxel delivery: Recent developments and prospects

Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use.

Recent progress in nanoformulations of cabazitaxel